Opendata, web and dolomites

Outsense Phase-1 SIGNED

Toilet IoT sensor for medical monitoring and wellness tool

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "Outsense Phase-1" data sheet

The following table provides information about the project.

Coordinator
OUTSENSE DIAGNOSTICS LTD 

Organization address
address: MOBILE POST HOF-HACARMEL
city: KIBBUTZ NAHSHOLIM
postcode: 3081500
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website https://outsense.co.il
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.1.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT))
2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-10-01   to  2018-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    OUTSENSE DIAGNOSTICS LTD IL (KIBBUTZ NAHSHOLIM) coordinator 50˙000.00

Map

 Project objective

Colorectal Cancer (CRC) is considered one of the deadliest forms of cancer. CRC incidence and mortality can be reduced through screening. However, screening participation remains suboptimal worldwide, and though early screening is highly encouraged, more than hundreds of thousands die of the disease every year i.e. 50K people died only in The US in 2015. Screening for CRC is the process of identifying polyps that appear years before the appearance of symptoms of the disease. Several tests can be used to screen for colorectal cancers. These tests can be divided into: 1. Tests that can find both colorectal polyps and cancer: These tests look at the structure of the colon itself to find any abnormal areas. This is done either with a scope put into the rectum or with special imaging (x-ray) tests. Polyps found during these tests can be removed before they become cancerous, so these tests may prevent colorectal cancer. These tests are effective but suffer from low compliance. 2. Tests that mainly find markers for cancer: These tests check the stool (faeces) for signs of cancer (usually blood). These tests are simpler, but less accurate and also suffer from low compliance However, currently these tests for early screening CRC suffer from 3 main problems and limitations: 1. Present low accuracy: can miss information (may fail in the detection of polyps, cover partially parts of the colon, false positives, etc.) 2. Create discomfort (Sedation may be needed, side effects –i.e. bloating, cramping- are usual) 3. May require stool handling that leads to low compliance. Clearly, there is a real need for a more accurate and less invasive test that will also increase compliance. Outsense product is built over a successful methodology with 3 fundamental pillars: (i) Optical method with high sensitivity and accuracy through the realization of multiple repetitive tests (ii) seamless solution, not requiring any stool handling, expected to lead to higher compliance (iii) direct commun

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OUTSENSE PHASE-1" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OUTSENSE PHASE-1" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.1.;H2020-EU.2.3.1.)

Starcounter (2017)

In-Memory Computing and Artificial Intelligence Platform for Building Next Generation Enterprise Software

Read More  

scanvid (2017)

ScanVid - One-Click Integrated Access to Product-related Digital Content

Read More  

oWBI (2018)

Osmotic Wearable Bolus Injector (oWBI) for viscous drug delivery

Read More